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Pathogenic gain-of-function mutations in the gene encoding phosphoinositide 3-kinase 
delta (PI3Kδ) cause activated PI3Kδ syndrome (APDS), a disease characterized by 
humoral immunodeficiency, lymphadenopathy, and an inability to control persistent viral 
infections including Epstein–Barr virus (EBV) and cytomegalovirus (CMV) infections. 
Understanding the mechanisms leading to impaired immune response is important 
to optimally treat APDS patients. Immunosenescence of CD8+ T cells was suggested 
to contribute to APDS pathogenesis. However, the constitutive activation of T cells in 
APDS may also result in T cell exhaustion. Therefore, we studied exhaustion of the CD8+ 
T cell compartment in APDS patients and compared them with healthy controls and HIV 
patients, as a control for exhaustion. The subset distribution of the T cell compartment 
of APDS patients was comparable with HIV patients with decreased naive CD4+ and 
CD8+ T cells and increased effector CD8+ T cells. Like in HIV+ patients, expression of 
activation markers and inhibitory receptors CD160, CD244, and programmed death 
receptor (PD)-1 on CD8+ T cells was increased in APDS patients, indicating exhaustion. 
EBV-specific CD8+ T cells from APDS patients exhibited an exhausted phenotype that 
resembled HIV-specific CD8+ T cells in terms of inhibitory receptor expression. Inhibition 
of PD-1 on EBV-specific CD8+ T cells from APDS patients enhanced in vitro proliferation 
and effector cytokine production. Based on these results, we conclude that total and 
EBV-specific CD8+ T cells from APDS patients are characterized by T cell exhaustion. 
Furthermore, PD-1 checkpoint inhibition may provide a possible therapeutic approach to 
support the immune system of APDS patients to control EBV and CMV.
Keywords: activated phosphoinositide 3-kinase delta syndrome, p110δ, Pi3K, cD8+ T  cells, exhaustion, 
programmed death receptor-1, checkpoint inhibition
inTrODUcTiOn
The phosphoinositide 3-kinase–AKT (PI3K–AKT) signaling pathway is involved in many crucial 
cellular processes including regulation of metabolism, proliferation, apoptosis, cell cycle regulation, 
and protein synthesis (1–3). In human lymphocytes, the phosphoinositide 3-kinase delta (PI3Kδ) 
isoform, a heterodimer consisting of the catalytic subunit p110δ (encoded by PIK3CD) and 
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regulatory subunit p85α (encoded by PIK3R1), is essential for 
both B  cell and T  cell development and maturation (4–7). For 
CD8+ T cells, PI3Kδ has been shown to be essential for optimal 
immune responses to pathogens (8, 9).
Over the past years, patients with gain-of-function (GOF) 
mutations in PI3Kδ have been described (10–12). These patients 
suffer from a specific form of primary immune deficiency called 
activated PI3Kδ syndrome (APDS) (13, 14). This disease is char-
acterized by disturbed humoral immunity resulting in hypogam-
maglobulinemia, recurrent respiratory tract infections an absent 
response to polysaccharide vaccination, pulmonary damage, 
lymphadenopathy, hepatosplenomegaly, an increased risk for 
hematological malignancies, and an inability to control persistent 
viral infections such as Epstein–Barr virus (EBV) and cytomeg-
alovirus (CMV) infections (13, 14). Immunophenotypically, these 
patients have decreased numbers of total CD4+ and especially 
naive CD4+ T cells together with increased CD8+ effector T cells. 
Furthermore, they have a relative increase in their transitional 
B  cells accompanied by reduced memory B  cells (15). Several 
studies indicated that the effector function of their T  cells is 
defective, causing an inability to control chronic viral infections 
including CMV and EBV infections (13, 14).
Impaired T cell effector function can be caused by different 
mechanisms, one of which is senescence (16, 17). Hallmarks of 
senescence are permanent cell cycle arrest (18, 19) and resistance 
to apoptosis (20, 21). Importantly, senescent T cells are metaboli-
cally and functionally active and retain their cytotoxic functions 
and ability to produce and secrete cytokines (22, 23). Reduced 
telomere length and surface-expression of CD57 were used to 
define senescent T cells. However, to reliably distinguish senes-
cence from other causes of T cell impairment additional markers 
like senescence-associated β-galactosidase and cyclin-dependent 
kinase inhibitor 2A (p16Ink4A) can be used (24, 25). Although 
senescence is age dependent, other factors such as CMV infection 
can contribute to senescence (26).
Exhaustion of T cells due to chronic antigenic stimulation is 
another mechanism leading to impaired T cell effector functions. 
T cell exhaustion was first described in chronic viral infections 
such as lymphocytic choriomeningitis virus infection in mice 
(27–29) but is also recognized as an underlying mechanism in 
immunological failure in human viral infections including HIV 
infection (30–33) and tumors (34–36). Exhaustion is a hier-
archical process (37, 38) by which CD8+ T cells first lose their 
proliferative capacity and IL-2 secretion, followed by diminished 
secretion of effector cytokines such as tumor necrosis factor 
(TNF) α and interferon (IFN) γ and eventually they become 
sensitive to apoptosis, which leads to the loss of these cells (29, 
38, 39). Simultaneously, these cells upregulate several inhibitory 
receptors including programmed death receptor (PD)-1, CD160, 
and CD244 which, when co-expressed, indicate later stages of 
exhaustion (40–43). These inhibitory receptors are considered 
to play a central role in exhaustion. Blocking these inhibitory 
receptors on exhausted CD8+ T cells can restore or improve their 
function in chronic viral infections as shown in  vitro (41, 42, 
44–46) and in vivo (40, 47–51). In addition, inhibitory receptor 
blockade was introduced into the clinic to re-activate exhausted 
T cells in cancer (52, 53).
Previously, total and virus-specific CD8+ T  cells in APDS 
patients were shown to have upregulated CD57 expression and 
reduced proliferative capacity. These findings were interpreted 
as T cell senescence (12, 54–56). However, patients’ lymphocytes 
also exhibited an increased rate of apoptosis compared with 
healthy controls (11, 15, 54), which is not in line with the resist-
ance to apoptosis that has been ascribed to T  cell senescence 
(21). Increased apoptosis sensitivity is associated with exhaustion 
rather than senescence (39, 57). In addition, APDS patient T cells 
have been reported to express more PD-1, a receptor associated 
with T  cell activation and exhaustion (12, 54, 55). The PI3Kδ 
pathway is critical for TCR signaling in CD8+ T cells (58) and 
chronic antigen stimulation alone is sufficient to lead to CD8+ 
T  cell exhaustion (59). This raises the question whether GOF 
mutations in PI3Kδ lead to changes in the activation of T cells 
which might predispose for T cell exhaustion rather than or in 
addition to immune senescence. Understanding the mecha-
nisms leading to impaired immune response in APDS patients 
is a requirement to define the best treatment options for these 
patients that can support the control of viral infections, which 
could in turn reduce virus-related morbidities in these patients.
To elucidate the role of exhaustion in APDS patients, total 
CD8+ T cells and CD4+ T cells from APDS patients were pheno-
typically characterized and compared with T cells from healthy 
individuals and HIV-infected patients (HIV+ patients). We have 
included peripheral blood mononuclear cells (PBMC) from HIV-
infected patients since it is well established that HIV infection 
leads to exhaustion of HIV-specific CD8+ T cells but not CMV-
specific CD8+ T cells in HIV-infected patients (39, 41) and can 
therefore serve as a positive control for exhaustion. Furthermore, 
virus-specific CD8+ T  cells in all three groups were character-
ized, and the effect of PD-1 blockade on proliferation and effector 
functions was investigated. Our findings indicate that indeed 
CD8+ T cells from APDS patients are more similar to the ones 
from HIV+ patients and exhibit characteristics of exhaustion. 
Importantly, we show that blocking PD-1 signaling can increase 
virus-specific CD8+ T cell proliferation and cytokine production. 
Our findings suggest that CD8+ T cells in APDS patients undergo 
exhaustion, and that this may contribute to the impaired control 
of persistent viral infections such as EBV and CMV. These find-
ings raise the possibility of checkpoint inhibition as a treatment 
strategy to support APDS patients to control recurrent or chronic 
viral infections.
MaTerials anD MeThODs
cell samples and ethical approval
This study was carried out in accordance with the recommenda-
tions of Erasmus MC Medical Ethics Committee with written 
informed consent from all subjects. All subjects gave written 
informed consent in accordance with the Declaration of Helsinki. 
The protocol was approved by the Erasmus MC Medical Ethics 
Committee.
Ten APDS patients were included with a median age of 27 years 
(range 6–44 years), and a gender ratio of six males to four females. 
Nine of the patients have a mutation in the PIK3CD gene (seven 
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patients: E1021K mutation, one patient: S312R mutation, and one 
patient: R929C mutation) (15), and one patient has a mutation 
in the PIK3R1 gene (N564K). From the patients including in 
this study, 9/10 received immunoglobulin substitution therapy, 
and 4/10 received prophylactic antibiotics. None of the patients 
received steroids or immune modulating drugs at the time of 
sampling. None of the APDS patients had active EBV or CMV 
infection at the time of sampling. Three of the APDS patients are 
EBV-antibody positive, and two are EBV-antibody negative, for 
the other patients the EBV status is not known. CMV status is 
not known from these APDS patients. From the healthy controls, 
nine are EBV positive. The five HIV-infected patients included 
have a median age of 42 years (range 35–46), gender ratio is one 
female to four males, three patients have undetectable viral loads 
(below 20 HIV copies/ml), and two have detectable viral loads 
(295 and 4,900 copies/ml, respectively). The median CD4 count 
is 300  cells/μl (range 50–630 cells/μl), and four out of the five 
patients are on antiretroviral therapy. The 10 healthy control 
individuals included have a median age of 27 years (range 18–51) 
and a gender ratio of five males to five females.
Peripheral blood mononuclear cells were isolated from hep-
arinized venous blood by Ficoll-Hypaque (GE Healthcare Life 
Sciences) density centrifugation, frozen in freezing media [90% 
fetal bovine serum (FBS)/10% DMSO], and stored in liquid nitro-
gen until used. Clinical data were provided by treating physicians. 
Due to availability of material, not all tests could be performed 
on all samples.
Flow cytometric immunophenotyping
Peripheral blood mononuclear cells were thawed, rested for 
30–60  min at 37°C, and stained with previously determined 
optimal amounts of tetramers and antibodies. For phenotyping 
of surface antigens, 0.8–1 × 106 cells were washed with Facs wash 
[FW, Hanks’ buffered saline solution (Corning), 3% fetal bovine 
serum (Gibco), and 0.02% NaN3], stained with tetramer/antibody 
mix for 30  min at 4°C, washed two times with FW, and fixed 
with 1% paraformaldehyde. Anti-HLA-A2-PE antibodies (clone 
BB7.2) were used to identify HLA-A2+ donors. Virus-specific 
CD8+ T  cells were identified by using APC- or PE-conjugated 
HLA class I A*0201-β2-microglobulin tetramers loaded with 
HIV Gag p17 77–85 (SLYNTVATL) peptide, HIV Pol 476–484 
(ILKEPVHGV) peptide, EBV peptide (GLCTLVAML), and CMV 
peptide (NLVPMVATV) (all tetramers were prepared in the 
lab). The following directly conjugated monoclonal antihuman 
antibodies were used: CD3-BV421 (clone UCHT1), CD4-BV650 
(SK3), CD8-BV786 (RPA-T8), CD45RA-APC-H7 (HI100), 
CCR7-PE-CF594 and Alexa Fluor 700 (CD197, 150503), 
PD-1-BV711 (CD279, EH12.1), CD160-Alexa Fluor 488 (BY55), 
CD244-PE (eBioC1.7, eBioscience), HLA-DR-BV605 (G46-6), 
CD38-PE-Cy7 (HIT2), CD57-BV605 (NK-1), TNFα-FITC 
(MAb11, eBioscience), and IFNγ-PECy7 (4S.B3, eBioscience). 
All antibodies were purchased from BD Biosciences unless 
otherwise indicated. When AnnexinV-PerCP–Cy5.5 was used to 
exclude dead cells, 2.5 mM CaCl2 was added to all solutions.
Between 1 and 4 × 105 events were collected per sample within 
24 h after staining on an LSRFortessa (BD Biosciences, 4 lasers, 18 
parameters) and analyzed using FlowJo software (version 9.9.4, 
Tree Star). Data are represented as frequency within a defined 
population.
In Vitro Proliferation
To determine proliferative capacity of proliferation-dye-labeled 
virus-specific CD8+ T cells, thawed PBMC were incubated with 
0.1 µM of CellTrace Far Red Cell stain (Invitrogen) in PBS for 
20 min at 37°C, and free dye was removed by adding RPMI-10% 
FBS and incubating for 5 min at 37°C. Cells were spun down and 
resuspended in RPMI 1640 supplemented with 10% heat-inacti-
vated FBS, 2 mM l-glutamine, 100 U/ml penicillin, and 100 µg/
ml streptomycin sulfate and added to 24-well plates in a concen-
tration of 1 × 106 PBMC/ml. To inhibit PD-1/PDL-1 interaction, 
10 µg/ml of anti-PD-L1 antibody (CD274, MIH1, eBioscience) or 
isotype control (Mouse IgG1, eBioscience) was added, and cells 
were incubated for 30 min at 37°C. Virus-specific peptide in a 
concentration of 1 µg/ml was added then in appropriate wells: 
Gag peptide (SL9, SLYNTVATL, ANASPEC), Pol peptide (IV9, 
ILKEPVHGV, ANASPEC), CMV peptide (pp65, NLVPMVATV, 
ANASPEC), EBV peptide (BMLF1, GLCTLVAML, ANASPEC), 
EBV peptide pool (PepMix EBV BMLF1, JPT), or media alone 
(no peptide stimulation). Purified anti-CD28 (1  µg/ml, clone 
CD28.2, BD Biosciences) and anti-CD49d (1 µg/ml, clone 9F10, 
BD Biosciences) were added to all wells. Cells were incubated for 
5 days at 37°C in a 5% CO2 incubator. Cells were harvested on day 
5, counted and resuspended in RPMI-10% FBS/1 μg/ml Brefeldin 
A (GolgiPlug, BD Biosciences)/anti-CD28 (1 μg/ml)/anti-CD49d 
(1 µg/ml), and incubated for 6 h to determine cytokine produc-
tion of these cells. For intracellular staining for cytokines, PBMC 
were first stained for surface antigens, fixed and permeabilized 
(Cytofix/Cytoperm, BD Bioscience), incubated with the antibod-
ies (see above) for 60 min, washed two times with Perm/Wash 
Buffer (BD Biosciences), and fixed with 1% paraformaldehyde.
statistical analysis
All data sets were tested for normal distribution using the 
D’Agostino–Pearson omnibus test. Relative distributions of T cell 
subsets and comparisons of population frequencies data were 
analyzed using either the non-parametric Mann–Whitney U test 
or a T-test, dependent on whether or not the data were normally 
distributed (p  <  0.05 was considered statistically significant). 
When more than two data sets were analyzed in the same test, 
the Kruskal–Wallis test was performed, combined with a Dunn’s 
multiple comparisons test. Correlations were calculated using a 
Spearman model for correlation, since in the majority of groups 
at least one population was not normally distributed. Statistics 
were performed using the GraphPad Prism program (GraphPad 
Software, San Diego, CA, USA). Populations’ frequencies per 
group are represented as mean with SEM.
resUlTs
Patient characteristics
We included 10 patients with APDS. From one patient (Pt1), two 
samples were included, one taken at age 7 years, and one collected 
at age 25 years. For analysis of total CD4+ and CD8+ T cells, we 
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only included the adult sample. For analysis of virus-specific CD8+ 
T cells, we included samples from both time-points. Most of the 
patients have been described before (15). The majority of patients 
(n =  7) carried the previously described E1021K mutation in 
PIK3CD (11, 12), one carried an R929C mutation in PIK3CD, and 
one carried an N564K (15) GOF mutation in PIK3R1. One patient 
carried a missense variant c.935C>G (NM_005026.3) resulting in 
an amino acid change p.S312C (NP_005017.3) in PIK3CD. This 
latter variant is also found in the general population with a minor 
allele frequency of around 2% (SNP reference: rs61755420) (60) 
and can therefore not be classified as disease causing. However, 
this patient does suffer from antibody deficiency and autoim-
munity and increased phosphorylation of AKT in lymphocyte 
subsets was found (Wentink, unpublished data). Therefore, we 
decided to study the effect of this variant together with patients 
with known disease causing mutations. Two of the patients were 
HLA-A2-positive (including the patient with samples available 
as a child and an adult) and EBV-specific CD8+ T  cells were 
analyzed.
We compared the PBMC from APDS patients to PBMC from 
10 healthy controls and 5 HIV+ patients.
The Phenotype of T cells in aPDs Patients 
is Distinct from healthy controls and 
resembles hiV-infected Patients
Previous studies on the T  cell compartment of APDS patients 
showed a reduction of the naive CD4+ and CD8+ T cells and an 
increase in the CD8+ T  cell effector memory (EM) population 
(11–13). In our patient cohort, we observed a comparable skew-
ing of the T cell populations. The frequencies of CD45RA+CCR7+ 
naive CD4+ T cells were significantly decreased in APDS patients 
compared with healthy controls and comparable with the 
frequencies in HIV+ patients (Figures 1A,B). CD45RA+CCR7+ 
naive CD8+ T  cells were significantly reduced in our APDS 
patient cohort compared with the healthy controls although 
not as profound as observed in HIV+ patients (Figure  1C). 
Within memory CD4+ T cells, an increase in CD45RA−CCR7+ 
central memory (CM) cells was found for the APDS and the 
HIV+ patients compared with healthy controls (Figure 1D). The 
CD45RA−CCR7− EM CD4+ T cell frequencies were not signifi-
cantly different when healthy controls, APDS and HIV+ patients 
were compared (Figure  1D). Frequencies of CM CD8+ T  cells 
were comparable between healthy controls and APDS patients as 
were the CD45RA+CCR7− EM re-expressing CD45RA (EMRA) 
CD8+ T cell populations (Figure 1E). A significant increase was 
found for the CD45RA−CCR7− EM CD8+ T cell population for 
APDS patients and HIV+ patients when compared with healthy 
controls. These findings indicate that both patient populations 
show comparable reduction of naive T cells and increased EM 
CD8+ T cells (Figure 1E).
To examine the effect of the GOF mutations on chronic activa-
tion we determined the expression of several chronic activation 
markers on T cells from healthy controls, APDS patients and HIV+ 
patients. The frequency of CD38brightCD8+ T cells was increased 
in APDS patients compared with healthy controls; however, HIV+ 
patients had an even higher percentage of CD38brightCD8+ T cells 
(Figure 2A). Although the frequency of CD38brightCD4+ T cells 
was also higher in APDS patients compared with healthy controls 
this was not significant (Figure 2D). HLA-DR was examined as 
a second marker of chronic activation, and indeed a significant 
increase was found for HIV+ patients within the CD8+ T  cell 
population. HLA-DR expression was significantly increased on 
CD8+ T cells (Figure 2B) and CD4+ T cells (Figure 2E) from the 
APDS patients compared with healthy controls.
We studied the expression of CD57 on CD8+ and CD4+ 
T  cells, since this was reported to be increased in a subset of 
APDS patients. We found that in APDS patients 34.9 ±  5.0% 
(mean ±  SEM) of CD8+ T  cells express CD57, compared with 
25.2 ± 4.0% in healthy controls and 56.4 ± 5.2% in HIV+ patients 
(Figure 2C). This indicates that although CD57+CD8+ T cells are 
increased in APDS patients, this is not significantly different from 
the frequency in healthy controls and lower than the frequency 
in HIV+ patients. A small but non-significant increase of CD57+ 
cells was also found within the CD4+ T cell population of APDS 
patients compared with healthy controls (Figure 2F). Overall, the 
expression of activation markers and CD57 indicate that T cells 
from APDS patients tend to be more activated than healthy 
controls and are therefore more alike T cells from HIV+ patients.
aPDs Patients have increased inhibitory 
receptor expression on cD8+ T cells
Since exhaustion is a gradual process in which cells over time co-
express multiple inhibitory receptors, we studied both the single 
expression of PD-1, CD160, and CD244 and co-expression of these 
three receptors on CD8+ T cells (Figures 3A–E). As we observed 
with the activation markers, the expression profile of inhibitory 
receptors within the APDS patients is very heterogeneous, with 
some patients in the range of controls and others in the range of 
HIV+ patients. We observed a significantly higher percentage of 
CD8+ T cells from APDS patients expressing CD160 compared 
with controls (mean 38 ± 6.0 and 21 ± 4.5%, respectively). This 
frequency in APDS patients was closer to HIV+ patients (mean 
50 ± 6.8%) (Figure 3B). The frequency of CD244-expressing CD8+ 
T cells within APDS patients and HIV+ patients was significantly 
increased compared with healthy controls (Figure 3C). PD-1 was 
also found increased on CD8+ T cells in APDS patients compared 
with controls (mean 38.8 ±  6.5 and 23.6 ±  6.9%, respectively) 
(Figure 3D). Most importantly, we observed a significant increase 
in the frequency of CD8+ T cells expressing all three inhibitory 
receptors, PD-1, CD244, and CD160 (PD-1+CD160+CD244+), in 
the APDS patients which was 20 ± 5.6% compared with 6 ± 2.3% 
PD-1+ CD160+CD244+CD8+ T cells in healthy controls. This fre-
quency of PD-1+CD160+CD244+CD8+ T cells in APDS patients is 
comparable with the one observed in HIV+ patients (21 ± 7.6%).
We examined whether a history of EBV infection influences 
the expression of inhibitory receptors on CD8+ T cells. From the 
APDS patients, EBV status information was available from five 
individuals, with three being EBV-antibody positive and two 
being EBV-antibody negative. We compared the expression of 
inhibitory receptors on CD8+ T cells from these two groups to the 
expression of the inhibitory receptors on the CD8+ T cells in the 
nine EBV-positive healthy controls. We found that the frequency 
FigUre 1 | Immunophenotyping of the T-cell compartment of controls (black dots), activated PI3Kδ syndrome (APDS) patients (black squares), and HIV+ patients 
(black triangles). Red lines and brackets indicate the mean and SEM of each group (*p < 0.05 and **p < 0,005). (a) Representative dot plots of controls and 
patients indicating naive (CD45RA+CCR7+), central memory (CM) (CD45RA−CCR7+), effector memory (EM) (CD45RA−CCR7−), and EMRA (CD45RA+CCR7−) CD8+ 
and CD4+ T cell subsets. Numbers depict frequency of cell populations. (B,c) The frequency of naive CD4+ T cells (B) and CD8+ T cells (c) is reduced in APDS 
patients and HIV+ patients compared with controls. (D) The frequency of CM CD4+ T cells is increased in APDS patients and HIV+ patients. The frequency of the 
different memory CD4+ T cells in controls, APDS patients, and HIV+ patients is shown. (e) The frequency of EM CD8+ T cells is increased in APDS patients and HIV+ 
patients. The different memory CD8+ T cell subpopulations are shown for controls, APDS patients and HIV+ patients.
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FigUre 2 | Expression of CD38, HLA-DR, and CD57 on CD8+ and CD4+ T cells from controls (black dots), activated PI3Kδ syndrome (APDS) patients (black 
squares), and HIV+ patients (black triangles). Red lines and brackets indicate the mean and SEM of each group (*p < 0.05 and **p < 0,005). (a) The frequency of 
CD38bright cells is increased in APDS patients and HIV+ patients compared with controls. The frequencies of CD38bright cells within CD8+ cells are shown for healthy 
controls, APDS and HIV+ patients. (B) The frequency of HLA-DR+ cells is increased in APDS patients and HIV+ patients compared with controls. Frequencies of 
HLA-DR+ cells within CD8+ T cells are shown. (c) Frequency of CD57+CD8+ T cells is not increase in APDS patients. Frequencies of CD57+ cells within CD8+ cells 
shown for healthy controls, APDS patients, and HIV+ patients. (D) Frequency of CD38+CD4+ T cells is comparable in healthy controls, APDS patients, and HIV+ 
patients. (e), Frequency of HLA-DR+CD4+ T cells is increased in APDS patients. Frequency of HLA-DR+ cells within CD4+ T cells shown for healthy controls, APDS 
patients, and HIV+ patients. (F) Frequency of CD57+CD4+ T cells is not increased in APDS patients compared with healthy controls. Frequency of CD57-expressing 
cells within CD4+ T cells shown.
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of CD160+, CD244+, PD-1+, and CD160+CD244+PD-1+CD8+ 
T  cells is highest in the EBV+ APDS patients (CD160+CD8+: 
57 ±  4.9%; CD244+CD8+: 87 ±  3.4%; PD-1+CD8+: 61 ±  8.2%; 
CD160+CD244+PD-1+CD8+: 36 ± 5.6%), but lower in the EBV− 
APDS patients and the EBV+ healthy controls (CD160+CD8+: 
26 ± 3.8 and 22 ± 4.7%; CD244+CD8+: 43 ± 5.3 and 48 ± 5.9%; 
PD-1+CD8+: 18  ±  3.0 and 25  ±  7.6%; CD160+CD244+PD-
1+CD8+: 5.6 ± 1.5 and 7.0 ± 2.5% for EBV− APDS patients and 
EBV+ healthy control, respectively). Thus, EBV-antibody positiv-
ity is accompanied by increased inhibitory receptor expression 
on CD8+ T cells.
We next analyzed whether reduced naive CD8+ T cell frequency 
and PD-1+CD160+CD244+CD8+ T  cells correlate in healthy 
controls and APDS patients. Although a negative correlation 
was already observed for healthy controls (Figure 3F), the cor-
relation between the frequencies of PD-1+CD160+CD244+CD8+ 
T cells and naive CD8+ T cells was highly significant in APDS 
patients (Figure  3F). For the HIV+ patients, this relationship 
was not significantly correlated. These results indicate that 
total CD8+ T  cells from APDS patients have increased co-
expression of inhibitory receptors similar to what is observed 
in HIV+ patients. Furthermore, the negative correlation of 
PD-1+CD160+CD244+CD8+ T  cells and naive CD8+ T  cells 
indicates that exhaustion in this compartment is associated with 
the skewed subset distribution.
Virus-specific cD8+ T cells from aPDs 
Patients exhibit an exhaustion Phenotype
To further compare exhaustion in APDS patients to exhaustion 
due to HIV infection, we analyzed virus-specific CD8+ T  cells 
in both patient groups and healthy controls. HIV-specific CD8+ 
T cells from HIV+ patients are highly sensitive to apoptosis, pre-
sent with a skewed memory phenotype, have proliferative defects, 
and show increased expression of inhibitory receptors (29, 38, 
39). However, in the same HIV+ patients, CMV-specific CD8+ 
T cells are not impaired. Using peptide-loaded HLA-A2 tetram-
ers, virus-specific CD8+ T cells were analyzed from three APDS 
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FigUre 3 | Continued
FigUre 3 | Expression of inhibitory receptors on CD8+ cells from controls (black dots), activated PI3Kδ syndrome (APDS) patients (black squares), and HIV+ 
patients (black triangles). Red lines and brackets indicate the mean and SEM of each group (*p < 0.05 and **p < 0,005). (a) Representative dot plots of controls 
and patients indicating populations that were considered positive for inhibitory receptors. (B) CD160 expression is increased on CD8+ T cells from APDS patients 
and HIV+ patients compared with controls. (c) CD244 expression is increased on CD8+ T cells from APDS patients and HIV+ patients compared with controls. (D) 
Programmed death receptor (PD)-1 expression is increased on CD8+ T cells from APDS patients but not HIV+ patients compared with controls. (e) The frequency of 
PD-1+CD160+CD244+CD8+ T cells is increased in APDS patients and HIV+ patients compared with controls. (F) The frequency of PD-1+CD160+CD244+CD8+ T cells 
is negatively correlated with the frequency of naive CD8+ T cells in controls and APDS patients.
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patients (EBV-specific CD8+ T  cells), five HIV+ patients (HIV 
Gag- or Pol-specific CD8+ T cells, CMV-specific CD8+ T cells), 
and four healthy controls (EBV-specific CD8+ T  cells). Within 
the three APDS samples are two different donors with one donor 
being represented as a child (7 years, red square in Figure 4) and 
as an adult (25 years, open square).
The virus-specific CD8+ T  cells in all four groups have a 
predominantly CD45RA−CCR7− EM phenotype (Figure  4A) 
which is lowest in CMV-specific CD8+ T cells from HIV+ patients 
since these cells have the highest frequency of more differenti-
ated EMRA (Figure 4A). No clear difference was observed for 
the frequencies of the chronic activation markers CD38 and 
HLA-DR when the four virus-specific CD8+ T cell groups were 
compared (Figure  4B). All virus-specific cells have higher fre-
quencies of CD38+ and HLA-DR+ cells than total CD8+ T cells 
(Figures  2A,B) from the same groups. CD57-expressing cells 
seem to be more abundant within EBV-specific CD8+ T  cells 
from APDS patients and CMV-specific CD8+ T cells from HIV 
patients than in EBV-specific CD8+ T cells from healthy controls 
and HIV-specific CD8+ T cells from HIV patients.
To assess exhaustion in the virus-specific CD8+ T cell popula-
tion, the expression of PD-1, CD160, and CD244 was analyzed 
(Figure 5). The mean percentage of CD244+ CD8+ T cells was 
above 90% in all virus-specific CD8+ T  cell groups. Frequency 
of CD160 expression slightly increased on HIV-specific CD8+ 
T cells compared with the other groups. The frequency of PD-1 
expressing CD8+ T  cells was lowest in CMV-specific CD8+ 
T cells from HIV+ patients and EBV-specific CD8+ T cells from 
healthy controls but higher within EBV-specific CD8+ T  cells 
from APDS patients and HIV-specific CD8+ T cells from HIV+ 
patients. We found that within the HIV-specific CD8+ T  cells 
71  ±  4.0% express all three inhibitory receptors, and within 
the EBV-specific CD8+ T cells from APDS patients 47 ± 10.6% 
express all three inhibitory receptors. EBV-specific cells from 
controls and CMV-specific cells from HIV+ patients have a lower 
frequency of PD-1+CD160+CD244+ populations (32 ±  3.2 and 
23 ± 5.2%, respectively). Compared with overall CD8+ T cells, all 
virus-specific CD8+ T cells show increased expression of inhibi-
tory receptors.
PD-1 Blockade can enhance In Vitro 
Proliferation of Virus-specific cells in 
aPDs and hiV+ Patients
Although both senescent and exhausted cells do not proliferate, 
the mechanism leading to the replicative impairment is different. 
In senescence, a cell cycle arrest causes the inability of cells to 
replicate whereas in exhaustion receptor-ligand interaction (such 
as between the inhibitory receptor PD-1 and its ligand PD-L1) 
leads to inhibition of TCR-signaling and therefore inhibition of 
proliferation. Thus, blocking the interaction between receptor and 
ligand through checkpoint inhibitors could lead to an increase in 
proliferation of exhausted cells, as shown for HIV-specific CD8+ 
T cells from HIV+ patients (44–46) but not in senescent cells. We 
stimulated PBMC from HIV+ patients and APDS patients with 
virus-specific peptide in the presence of blocking anti-PD-L1 
or isotype control antibodies for 5 days before analysis of pro-
liferation and effector function. As reported previously (44–46), 
inhibition of PD-1/PD-L1 interaction increased proliferation of 
HIV-specific CD8+ T cells in two out of the four tested PBMC 
samples from HIV+ patients by ~2-fold (Figure 6). When PBMC 
from APDS patients were stimulated with EBV-peptides in the 
presence of anti-PD-L1 antibodies, proliferation was increased in 
all three samples compared with samples stimulated with peptide 
in the presence of an isotype control. Not only did we observe 
improved proliferation of these cells but also increased effector 
function as demonstrated by the frequency of cytokine-producing 
cells (Figure  6). The patient with the highest proliferative and 
effector cytokine response was also the patient with the highest 
frequency of PD-1+ and PD-1+CD160+CD244+ EBV-specific 
CD8+ T cells. These findings indicate that PD-1 signal inhibition 
not only increased proliferation but also enabled these cells to 
release effector cytokines including IFNγ and TNFα. These results 
suggest that exhausted EBV-specific CD8+ T  cells from APDS 
patients can be functionally restored through checkpoint inhibi-
tors, resulting in increased proliferation and effector functions.
DiscUssiOn
How T cell defects due to GOF mutations of PI3Kδ contribute to 
morbidity in APDS patients is not fully understood. The goal of 
this study was to determine whether the GOF mutations in PI3Kδ 
(causing APDS) lead to exhaustion of CD8+ T cells. Furthermore, 
we determined whether virus-specific CD8+ T cells against recur-
rent or persistent infections such as EBV are exhausted in APDS 
patients and if immune-checkpoint blockade can rejuvenate 
exhausted CD8+ T cells in APDS patients. We compared CD8+ 
T cells from APDS patients to healthy controls and HIV+ patients, 
which served as a control for antigen induced exhaustion of 
CD8+ T cells. Understanding the effect these mutations have on 
the immune system is central to further treatment strategies to 
support these patients in controlling chronic infections like EBV 
and CMV to reduce morbidity and mortality.
In line with previous reports (13, 14), we found significantly 
reduced frequencies of naive CD4+ and CD8+ T cells in APDS 
patients. Loss of naive T cells is thought to be caused by hyperac-
tivation of the mTOR pathway induced by PI3Kδ mutations. This 
FigUre 4 | Phenotyping and activation marker expression on Epstein–Barr virus (EBV)-specific CD8+ T cells from controls (black dots), EBV-specific CD8+ T cells from 
activated PI3Kδ syndrome (APDS) patient 1 at the age of 7 years (red square), at the age of 25 years (open square), APDS patient 2 (black square), HIV-specific CD8+ 
T cells from HIV+ patients (black triangles), and cytomegalovirus (CMV)-specific CD8+ T cells from HIV+ patients (open triangles). Red lines and brackets indicate the 
mean and SEM of each group (*p < 0.05 and **p < 0,005). (a) Frequency of memory subpopulations [central memory (CM), effector memory (EM), and EMRA, CCR7+ 
memory (CD45RA+CCR7+)] within virus-specific CD8+ T cells shown for healthy controls (EBV-specific CD8+ T cells), APDS patients (EBV-specific CD8+ T cells), and 
HIV+ patients (HIV- and CMV-specific CD8+ T cells). (B) Frequency of CD38+ (left), HLA-DR+ (center), and CD57+ (right) cells shown within virus-specific CD8+ T cells.
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leads to increased glycolysis, proliferation, and differentiation 
into short-lived effector cells (11, 12). The APDS patients showed 
a skewed CD8+ T  cell subset distribution, with increased EM 
CD8+ T cells, which we also found in HIV+ patients. Impaired 
control of viral infection could be an underlying mechanism 
causing the increased EM pool in HIV+ patients. In APDS 
patients, chronic and/or recurrent viral infections such as EBV 
and CMV on top of the GOF mutation are likely to contribute to 
this phenotype. Interestingly, although the EM population is also 
slightly increased in CD4+ T cells, it is the CM population which 
is significantly higher in both patient groups.
To further examine the effect of PI3Kδ GOF mutations on 
the total CD4+ and CD8+ T cell compartments, we analyzed the 
expression of the chronic activation markers CD38 and HLA-DR. 
Especially HLA-DR was shown before to correlate with immune 
activation and disease progression in HIV infection (61). 
This is the first time that these chronic activation markers are 
analyzed on T  cells from APDS patients. HLA-DR expression 
FigUre 5 | Continued
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FigUre 6 | Proliferation and effector cytokine production in vitro of Epstein–Barr virus-specific CD8+ T cells from activated PI3Kδ syndrome (APDS) patients and 
HIV-specific CD8+ T cells from HIV+ patients after peptide stimulation in the presence of anti-programmed death receptor (PD)-L1 antibodies or isotype controls. (a) 
Representative dot plots showing cytokine-producing and proliferated CD8+ T cells after 5-day peptide stimulation of peripheral blood mononuclear cells from an 
APDS patient in the presence of isotype control (upper panel) or anti-PD-L1 monoclonal antibodies (lower panel). Gates indicate cells positive for interferon (IFN) γ, 
tumor necrosis factor (TNF) α, or cells with diluted cell-trace proliferation dye. (B) Anti-PD-L1 antibody treatment resulted in increased proliferation and production of 
TNFα and IFNγ upon peptide stimulation in both APDS and HIV+ patients. Pooled data showing fold change of the frequency of either cells undergoing proliferation 
or cytokine-producing cells in the presence of anti-PD-L1 antibody over isotype control. Cells were stimulated with viral peptide for 5 days in the presence of 
monoclonal antibodies. Red lines and brackets indicate the mean and SEM of each group.
FigUre 5 | Inhibitory receptor expression on virus-specific CD8+ T cells from controls and patients. (a) Representative dot plots of healthy controls and patients 
indicating identification of virus-specific cells and inhibitory receptors positive cells within virus-specific populations. (B) Inhibitory receptor expression on Epstein–
Barr virus (EBV)-specific cells from controls (black dots), EBV-specific cells from activated PI3Kδ syndrome (APDS) patient 1 at the age of 7 years (red square), at the 
age of 25 years (open square), APDS patient 2 (black square), HIV-specific cells from HIV+ patients (black triangles), and cytomegalovirus (CMV)-specific cells from 
HIV+ patients (open triangles). Red lines and brackets indicate the mean and SEM of each group.
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was significantly increased on CD8+ and CD4+ T cells in APDS 
patients compared with healthy controls, and it is comparable 
with what is observed in HIV+ patients. Our findings indicate 
that a subpopulation of CD4+ and CD8+ T cells in APDS patients 
are chronically activated. However, APDS patients show great 
heterogeneity, with only a small part of T  cells expressing the 
chronic activation markers, our findings thus suggest that the 
mutation alone does not lead to a chronic activation of T cells. 
One exhaustion-inducing factor could perhaps be infection with 
a persistent virus; we therefore analyzed the expression of CD38 
and HLA-DR on CD8+ T cells specific for persistent viruses. We 
did not find significant differences in the expression of activation 
markers on virus-specific cells between controls, APDS patients, 
and HIV+ patients. Thus, we cannot at this moment conclude 
that infections with persistent viruses contribute to the higher 
frequency of HLA-DR+ T cells in APDS patients.
Some APDS patients have increased CD57 expression on 
CD8+ T  cells, and previously this was interpreted as increased 
senescence (12, 54, 55). The surface marker CD57 is commonly 
used as a senescence marker, but T cells in HIV+ patients also 
express increased CD57, indicating that exhaustion and senes-
cence can co-exist in patients (62–64). In our study cohort, the 
mean CD57+ T cell frequency in APDS patients is only slightly 
increased compared with healthy controls and much lower than 
that of HIV+ patients. However, the CD57 expression in the 
APDS cohort is very heterogeneous, with some patients com-
parable with controls and others in the range of HIV+ patients. 
CD57 expression levels were not correlated with age, gender, or 
mutation in our patient cohort. Neither was this correlated with 
clinical characteristics such as lymphadenopathy, autoimmunity, 
malignancies, the expression of other markers we studied here 
or with B-cell phenotypes. Our results suggest that senescence 
and exhaustion might not be totally separate processes, but rather 
two intertwined cellular states that can occur together in specific 
types of diseases such as APDS.
To further assess exhaustion in APDS patients, we analyzed 
the expression of the inhibitory receptors CD160, CD244, and 
PD-1. We have included PBMC from HIV-infected patients 
since it is well established that HIV infection leads to exhaus-
tion of HIV-specific CD8+ T cells but not CMV-specific CD8+ 
T cells in HIV-infected patients (39, 41) and can therefore serve 
as a positive control for exhaustion. We found that CD244+, 
CD160+, and PD-1+ CD8+ T  cells are significantly increased 
in APDS patients. CD8+ T cells expressing all three inhibitory 
receptors (PD-1+CD160+CD244+), which would indicate the 
most exhausted state, were also significantly increased in APDS 
patients and to a similar degree as in HIV-infected individuals. 
We did not find any correlates for the PD-1+CD160+CD244+CD8+ 
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T  cell population in APDS patients when age, gender, type of 
mutations, B  cell phenotype, or any other marker we have 
described were analyzed. When we separated the APDS patients 
in EBV-antibody positive and EBV-antibody negative, we found 
that the highest expression of the inhibitory receptors including 
the concurrent expression of all three inhibitory receptors was 
observed in EBV+ APDS patients. However, EBV− APDS patients 
had a frequency of inhibitory receptor expressing CD8+ T cells 
which was similar to the one from EBV+ healthy controls. These 
findings suggest that chronic EBV infection or antigen stimula-
tion in APDS patients contributes to the exhaustion of CD8+ 
T cells.
Within virus-specific CD8+ T cells, we found increased expres-
sion of inhibitory receptors in all subpopulations. Overall, the 
expression of inhibitory receptors on CD8+ T cells from APDS 
patients has more similarities with HIV+ patients, supporting the 
idea that the PI3Kδ GOF mutations may contribute to exhaustion. 
This was supported by the highly significant negative correlation 
between the frequency of naive and PD-1+CD160+CD244+CD8+ 
T  cells, indicating that the hyperactivation leading to reduced 
naive T cells, may also be responsible for the increased expression 
of inhibitory receptors on T cells. Our findings do not imply that 
signaling mechanisms leading to exhaustion is identical in APDS 
and HIV infection although chronic antigen exposure may play 
an important role in both APDS and HIV patients as has been 
suggested in mouse studies (59).
Commonly, exhaustion is studied in the context of chronic 
antigen stimulation due to chronic viral infections and cancer. 
In APDS, we see a similar increase of exhausted CD8+ T cells 
especially in patients that are EBV-antibody positive implying 
that chronic antigen stimulation contributes to T  cell exhaus-
tion. Chronic TCR stimulation is sufficient to lead to CD8+ T cell 
exhaustion (59). Since PI3Kδ participates in TCR signaling in 
T cells (58), a cell-intrinsic chronic activation due to the hyper-
activity of the PI3K–AKT signaling pathway could be a factor 
promoting the exhausted phenotype in the absence of specific 
chronic antigen in APDS. Since not all APDS patients’ T cells 
show a significant increase in inhibitory receptor expression, 
the PI3Kδ mutations may be necessary but not sufficient for 
exhaustion. One mechanism to lower the threshold for exhaus-
tion in APDS could be PI3K-induced epigenetic modifications. 
Several studies have shown epigenetic alterations in exhausted 
T cells (65, 66). The altered gene expression patterns induced by 
epigenetic modifications are rather stable resulting in permanent 
exhaustion independent of the level of remaining antigen (67, 
68). Demethylation of the PD-1 promotor region in exhausted 
CD8+ T cells allows sustained expression of PD-1. That PI3K can 
indeed alter epigenetic modifications was indicated in a study 
in mouse embryonic stem cells, suggesting that de novo DNA 
methyltransferases are downregulated due to PI3K-induced 
AKT, leading to reduced DNA methylation of imprinted loci 
(69). Therefore PI3Kδ GOF mutations could promote the 
demethylation of inhibitory receptors or reduce the threshold 
for such demethylation, thus facilitating the exhaustion in CD8+ 
T cells.
Over the past years, PD-1 blockade has been a subject 
of research in both HIV and cancer treatment. By blocking 
inhibitory receptors, exhausted CD8+ T cells can regain effec-
tors functions and provide antiviral or anti-tumor immunity. 
However, upregulation of inhibitory receptors on activated 
T cells has also a physiological function: they function as nega-
tive regulators, downregulating the immune response after 
successful control of infections (70, 71). They are important 
to prevent autoimmunity and pathological responses leading 
to tissue damage. In the absence of inhibitory receptors an 
increased risk for autoimmunity and immunopathology was 
reported (72–74). Upregulation of inhibitory receptors in 
APDS could be a protective mechanism to prevent damage 
through an overly activated immune system. This hypothesis 
is supported by a study, which showed how PD-1 signaling can 
prevent activation of PI3K and AKT phosphorylation, thereby 
preventing proliferation (75). This benefit of preventing auto-
immunity or inflammation in APDS comes at a cost of impair-
ing immunity to viruses. Indeed, we have seen an increase in 
proliferation and effector cytokine secretion in virus-specific 
CD8+ T cells from APDS patients in vitro in the presence of 
PD-L1 blocking antibodies. The increase of proliferation and 
cytokine production we have observed in the presence of a 
PD-L1 blocking antibody is moderate, and this raises the ques-
tion of biological significance. Since we have observed that the 
patient with the highest expression of PD-1 showed the highest 
increase in proliferation and cytokine-producing EBV-specific 
CD8+ T cells this suggests that the more responsive patients 
to PD-1 blockade will be the highest expressers. To more 
significantly improve the effector functions in all patients a 
combination of blocking several checkpoint inhibitors may 
be required, as indicated by PD-1/CTLA-4 blocking in cancer 
studies (76, 77) Furthermore, the increase of effector function 
is similar when EBV-specific CD8+ T cells from APDS patients 
are compared with HIV-specific T  cells from HIV-infected 
patients and within the range reported previously for HIV-
specific CD8+ T cells (41, 44, 45). Thus, short-term treatment 
of patients with checkpoint inhibitors during a recurrent EBV 
and/or CMV infection could be a means to augment efficacy 
of exhausted virus-specific CD8+ T cells and thus reduce EBV 
and CMV related morbidity. Because inhibitory receptor 
upregulation may possibly be beneficial in APDS by prevent-
ing excessive inflammation or autoimmunity, manipulating 
this pathway has to be done with caution, and ideally it should 
be combined with long-term treatment that can reduce the 
hyperactivation of the pathway, for example selective PI3K 
inhibition (78).
In summary, we have shown that CD8+ T  cells from APDS 
patients have an exhausted phenotype and upregulated expres-
sion of inhibitory receptors. This exhaustion of the CD8+ T cells 
contributes to the deficient antiviral capacities of the CD8+ T cell 
compartment. Blocking the PD-1–PD1L interaction could be a 
target for treatment in these patients during recurrent or persis-
tent viral infections.
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